Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Current Pharmaceutical Design|April 12, 2002
NR2B selective NMDA receptor antagonistsSham S Nikam, Leonard T Meltzer
Synapse (New York, N.Y.)|June 2, 2006
Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptorsMarc Morissette, Mehdi Dridi, Frédéric Calon, et al.
Journal of Molecular Neuroscience : MN|August 16, 2008
Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesiasBazoumana Ouattara, Samah Belkhir, Marc Morissette, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 30, 2005
Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalinMarc Morissette, Mehdi Dridi, Frédéric Calon, et al.
Neurobiology of Aging|March 14, 2007
mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeysPershia Samadi, Laurent Grégoire, Marc Morissette, et al.
Bioorganic & Medicinal Chemistry Letters|February 26, 2004
Subtype selective NMDA receptor antagonists: evaluation of some novel alkynyl analoguesBrian E Kornberg, Sham S Nikam, Jon L Wright, et al.
Journal of Medicinal Chemistry|May 31, 2002
A new type of prodrug of catecholamines: an opportunity to improve the treatment of Parkinson's diseaseBastiaan J Venhuis, Nienke Rodenhuis, Håkan V Wikström, et al.
Bioorganic & Medicinal Chemistry Letters|November 14, 2009
Synthesis and in vivo evaluation of 3,4-disubstituted gababutinsDavid C Blakemore, Justin S Bryans, Pauline Carnell, et al.
Pageof 2